Larimar Therapeutics (LRMR): President and COO bought ~$50K

~$50K

Approx. value · 18K sh @ $2.80

68K

Holds after · shares reported

Traded

Nov 11, 2026

Filed

Nov 12, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Sep 29, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“The Board of Directors (the “Board”) of Larimar Therapeutics, Inc. (the “Company”) appointed John B. Harlow, Jr. as the Company’s President and Chief Operating Officer pursuant to the terms of an employment agreement with Mr. Harlow (the “Employment Agreement”), effective as of September 29, 2026 (the “Effective Date”).”
2. Nov 9, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
3. Nov 11, 2026 · this disclosureInsider · 6 insiders in a week, a first since 2014Officer purchased ~$50K of LRMR shares in the open market

What came next

1. Nov 11, 2026Insider · 5 peopleInsiders: 5 purchases (~$145K)
2. Nov 12, 2026Insider · 7 insiders in a week, a first since 2014Director purchased ~$187K of LRMR shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Larimar Therapeutics

For Larimar Therapeutics, OQRO holds 7 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LRMR page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Larimar Therapeutics

• SEC Form 4Nov 13, 2026
• SEC Form 4Nov 12, 2026
• SEC Form 4Nov 12, 2026
• SEC Form 4Nov 12, 2026
• SEC Form 4Nov 12, 2026
• SEC Form 4Nov 12, 2026

Everything OQRO holds on this company is on its LRMR page.